Virtual mentorship program for parents of pediatric organ transplant recipients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The iParent2Parent (iP2P) program connects parents of pediatric solid organ transplant recipients with trained peer mentors through a virtual platform. This innovative approach aims to reduce feelings of isolation and improve mental health by providing one-on-one support. Parents will be randomized into either the iP2P program or a control group to assess the effectiveness of peer mentorship. The study leverages eHealth technologies to enhance access to support interventions for families navigating the challenges of pediatric organ transplantation.

Why it matters

Who can join: the full rules

Mentee Inclusion Criteria:

* Parent of a patient under 18 years of age who received a solid organ transplant and is at least two months post-transplant,
* Access to a device (e.g., smart phone, tablet, computer) capable of using free WhatsApp software, and
* English-speaking.

Mentor Inclusion Criteria:

* Parent of a patient under 21 years of age who received a solid organ transplant and is at least one year post-transplant,
* Nominated by their child's healthcare team as a good candidate to act in the mentor role (e.g., good communication skills, positive adaptation and adjustment post-transplant, strong support network),
* Access to a device (e.g., smart phone, tablet, computer) capable of using free WhatsApp software, and
* English-speaking.

Exclusion Criteria:

* Non-English speaking.

Where it's running

• Hospital for Sick Children
  Toronto, Ontario, Canada Recruiting

Study contacts

• Principal investigator: Samantha J. Anthony, PhD, MSW — The Hospital for Sick Children
• Study coordinator: Samantha J. Anthony, PhD, MSW
• Email: samantha.anthony@sickkids.ca
• Phone: 416-813-7654

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• A tablet game to help kids with solid organ transplants remember and learn their medicines

  A tablet-based educational game is being tested to see if it helps kids aged 7–17 on solid organ transplants learn about their meds and stay adherent.

  Recruiting Stanford University · Palo Alto, California · NCT07609303

• Genotype-informed dosing of tacrolimus for children after organ transplants

  This study tests if adjusting the dose of tacrolimus based on children's genetic makeup can help them after organ transplants by ensuring they get the right amount of the medication.

  Recruiting Phase 4 Murdoch Childrens Research Institute · Melbourne, Victoria · NCT06529536

• Understanding respiratory viral infections in pediatric transplant recipients

  This study is trying to see if measuring respiratory viruses before a transplant can help predict which kids might get respiratory infections afterward.

  Recruiting at 27 sites Arkansas Children's Hospital Research Institute · Birmingham, Alabama and 26 other locations · NCT05550298

• Delayed infusion of a naïve T cell–depleted hematopoietic graft with memory T cells for solid organ transplant recipients

  This early study will test whether giving a donor-derived stem cell graft that’s depleted of naïve T cells but includes memory T cells can safely help children and adults who receive kidney, lung, or multivisceral transplants tolerate the new organ with less long-term immune-suppressing medicine.

  Recruiting Phase 1 Hospital Universitario La Paz · Madrid, Madrid · NCT06997471

• Transplanting gut bacteria to improve outcomes in organ transplant patients

  This study tests whether transplanting gut bacteria can help organ transplant patients who are having stomach issues feel better and reduce complications.

  Recruiting The Second Hospital of Nanjing Medical University · Nanjing, Jiangsu · NCT06730451

• Treatment for Epstein-Barr Virus-Associated Lymphoproliferative Disease After Transplant

  This study is testing a new treatment called tabelecleucel for patients with a specific type of cancer related to Epstein-Barr virus who haven't improved with other therapies after receiving a transplant.

  Recruiting at 35 sites Phase 3 Pierre Fabre Medicament · Duarte, California and 70 other locations · NCT03394365

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.